Bioanalytical Characterization Of HIV Gp120 Vaccine Antigens And Its Relation To Vaccineinduced Antibody Response | 10178
Journal of Analytical & Bioanalytical Techniques
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
The viral envelope glycoprotein (Env) has been a key target for antibody-mediated vaccine development against human
immunodeficiency virus type 1 (HIV 1). Although several recombinant Env-based immunogens have been evaluated in
clinical trials, only gp120 proteins (Subtype B, MN, and Subtype A/E, A244) used in ALVAC prime-AIDSVAX gp120 boost
RV144 Phase III HIV vaccine trial have contributed to protective efficacy, although modest and short-lived. Therefore, as we
selected gp120 protein candidates from subtype C isolates for a post-RV144 proof-of-concept (POC) Phase I/II trial in Southern
Africa, we used a rational selection approach based on several pre-set criteria that included protein productivity, homogeneity,
antigenicity, and immunogenicity. This approach led to the identification of two gp120 antigens. Detailed analytical analysis of
the two CHO-produced gp120 proteins revealed glycan profiles and occupancy, monoclonal antibody binding and extent (and
impact) of heterogeneity during expression. Additional
analysis of the two gp120 protomers (gp120 monomer and dimer)
highlighted the disulfide ?scrambling?, particularly in V1V2-C1 region, leading to the generation of gp120 dimers. These gp120
dimers not only lacked binding to certain key epitope-directed monoclonal antibodies but also elicited little to no antibody
response directed to those epitopes, when immunized in rabbits, in contrast to monomeric gp120. In summary, we highlight
the rationale for overall selection of gp120 vaccine antigens based on thorough bioanalytical characterization to assist antigen
production for pivotal clinical trials in Southern Africa.
Antu K. Dey is Senior Scientist (in Exploratory and Early Clinical Development group) at Novartis Vaccines & Diagnostics. He completed his D.Phil.
in Biochemistry from University of Oxford followed by his post-doctoral training at Weill Cornell Medical College in New York City. His deep interest in
biochemical and biophysical characterization of vaccine antigens and rationale vaccine design led him to join Novartis Vaccines in 2008, and since
then he has been in positions of increasing responsibility. He has published several patents and peer-reviewed papers and has been serving as an
ad hoc reviewer and editorial board member for several journals.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals